EN | 中文
Biocytogen Submitted Form to Hong Kong Stock Exchange for IPO Application
Aug 30, 2021
According to documents from the Hong Kong Stock Exchange, Biocytogen has submitted IPO application, and Goldman Sachs and CICC are joint sponsors.

Biocytogen is a clinical stage biotechnology and preclinical research service company already generating revenues. It has built a high-throughput in vivo antibody discovery platform, proprietary gene editing technologies, transgenic mouse platform, and comprehensive animal patient models. The world's first large-scale in vivo antibody discovery and screening program initiated by Biocytogen is expected to become the fountain of a large number of first-in-class antibodies or best-in-class antibodies against new and/or difficult drug targets.

Source: https://baijiahao.baidu.com/s?id=1709478468916000816&wfr=spider&for=pc